Baidu
map

J Thromb Haemost: 抗血小板治疗患者颅内出血或严重出血的预测模型:meta分析

2015-12-31 phylis 译 MedSci原创

背景:广泛应用抗血小板治疗对TIA或缺血性卒中进行二级预防。出血是抗血小板治疗的主要不良反应,可能危及生命。抗血小板治疗时要注意识别出血风险较高的患者。目标:本研究旨在确定抗血小板治疗患者颅内出血或大出血的预测模型,并评估其在脑缺血患者的表现。方法:系统检索2014年到12月以前的PubMed和EMBASE中现有预测模型。应用CHARMS评估方法学质量。预测模型在欧洲卒中预防研究2中进行外部验证,

背景:广泛应用抗血小板治疗对TIA或缺血性卒中进行二级预防。出血是抗血小板治疗的主要不良反应,可能危及生命。抗血小板治疗时要注意识别出血风险较高的患者。

目标:本研究旨在确定抗血小板治疗患者颅内出血或大出血的预测模型,并评估其在脑缺血患者中的表现。

方法:系统检索2014年12月以前的PubMed和EMBASE中现有预测模型。应用CHARMS评估方法学质量。预测模型在欧洲卒中预防研究2中进行外部验证,包括6602例TIA或缺血性卒中患者。研究者评估预测模型的区分度和准确度。

结果:共识别了5个预测模型,其中2个为以前的脑缺血患者。三个研究评估了严重出血,一个研究颅内出血,一个研究评估消化道出血。所有研究都未达到良好质量的标准。外部效度显示区分度和准确度都较差,c统计量范围从0.53到0.64。

结论:预测抗血小板治疗引起的颅内出血或严重出血的预测模型较少。模型的方法学的质量较低。脑缺血患者的预测性能较差。根据当前的方法学的标准形成新的预测模型,准确预测脑缺血患者出血的风险是必要的。

原文出处:

Hilkens NA, Algra A, Greving JP. Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. J Thromb Haemost. 2015 Nov 12.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-07-08 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-09-28 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-01-02 milkshark

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-01-01 lu2996

    临床预测模型也是新的研究方法

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-01-01 lu2996

    肿瘤专业用的比较多的统计方法

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-01-01 lu2996

    支持

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-01-01 lu2996

    学习中

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1887496, encodeId=ae40188e4961c, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Jul 08 11:30:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895870, encodeId=78cb18958e0fb, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Sep 28 01:30:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51086, encodeId=b49651086c6, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jan 02 06:27:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262716, encodeId=5fbf1262e16a1, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 01:30:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50994, encodeId=e459509945a, content=临床预测模型也是新的研究方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50995, encodeId=24295099557, content=肿瘤专业用的比较多的统计方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50996, encodeId=d9a750996ae, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:22:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50993, encodeId=dc155099374, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Fri Jan 01 12:13:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008221, encodeId=8d14200822166, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu May 19 16:30:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 changfy

相关资讯

李焰生:脑小血管病之认知障碍的防治策略

在23日的第四届全国痴呆与认知障碍高级讲授班及学术研讨会上,上海交通大学医学院附属仁济医院李焰生教授做了《脑小血管病之认知障碍的防治》的报告,小编在此对其报告内容进行了整理,希望对您有所裨益! 一、减少血压变异性及平稳降压治疗策略为首选 1、高血压是脑小血管病(CSVD)的最重要危险因素,降压治疗能有效预防卒中的复发,还能预防认知功能的衰退和

JACC:阿哌沙班单抗或双重抗血小板治疗急性冠脉综合征效果

    目前,出血情况限制了急性冠脉综合征(ACS)的抗凝治疗。该研究对ACS后伴随抗血小板治疗是否会影响阿哌沙班的效果进行了调查。    本研究旨在探讨使用阿司匹林或阿司匹林加氯吡格雷治疗的高危急性冠脉综合征患者被随机分配接受每日两次阿哌沙班5毫克或安慰剂的效果。在事后分析中,研究人员评估是否阿哌沙班的疗效和安全性会随着伴随抗血小板方案的使用而变化,通过有

2015英国2型糖尿病指南[讨论稿]:降压与抗血小板治疗

河北省人民医院  郭艺芳英国国家健康与保健优化研究所(NICE)将于2015年9月颁布新一版成人2型糖尿病管理指南,现已公布新指南的初稿征集意见。新版指南重新梳理了现有研究结论,在2009年版指南基础上进行了修订。初稿公布后,其关于降糖治疗流程的建议迅即引起多位糖尿病专家的强烈质疑(特别是将瑞格列奈与吡格列酮作为二甲双胍之后首选的二线降糖药)。关于其他心血管危险因素的控制,新版指南未纳入

Stroke:正在服用阿司匹林的患者发生缺血性卒中该怎样抗血小板治疗?

背景和目的:当服用阿司匹林时发生缺血性卒中,在不同的抗血小板策略中选择是一种常见的临床挑战,目前尚缺乏相关处理的数据。方法:这项研究是分析韩国14家医院的前瞻性的多中心卒中注册表数据库中的数据。招募急性非心源性卒中的患者,在卒中发生时正服用阿司匹林预防缺血性事件的发生。研究者根据随后的抗血小板治疗策略将其分为3组;维持阿司匹林单药治疗(MA组)、应用非阿司匹林抗血小板药物(SA组),添加另一种抗血

Circulation:PCI后抗血小板治疗或无需监测血小板功能

尽管治疗期间血小板高反应性是冠脉疾病患者的一项缺血风险标志,且生物信息可用于调整抗血小板治疗,但在比较冠脉支架治疗患者未监测血小板功能(标准抗血小板治疗)与血小板功能监测(根据结果调整治疗)的随机研究中,一些随机研究发现两组临床结局无明显差异性。 2012年的ARCTIC研究有其独到之处,在介入治疗前就寻找和治疗对阿司匹林和氯吡格雷反应性差的患者,以期预防围手术期事件和远期事件。从介入治

JACC:血液稀释剂可降低血管成形术的死亡率

根据今天在JACC发表的一项研究:接受接受血管成形术的急性冠脉综合征患者可减少各种原因入医院死亡的风险,但当手术结束后给予糖蛋白2B/3A抑制剂(GPI)时,会增加出血的风险。研究人员使用来自国家心血管数据注册CathPCI注册表数据,评估了在2009年7月和2011年9月间970865例急性冠脉综合征患者的记录。尽管在支架的设计和新的抗凝血剂方面有许多进展,如比伐卢定,研究发现,研究中将近三分之

Baidu
map
Baidu
map
Baidu
map